Uncovr

The computer vision models are the entire product. Uncovr reads raw operating room video, segments the procedure into steps, instruments and events, and derives both the operative narrative and the codes from that segmentation. There is no video management platform, archive or workflow tool underneath that would retain value without the models, and the company was founded around the vision capability rather than adding it to an existing product.

A stated hard gate plus the most auditable output in this space, held back by one unanswered question. Uncovr states that output is clinician reviewed before every submission, so nothing files autonomously, and it staffs senior surgeons and expert medical coders against the output. The auditability is the standout: every CPT code is presented with linked evidence, meaning the passage of the report supporting it AND the video timestamp it was derived from. That is the Linked Evidence property this index credits in Abridge, applied to a billing code and anchored to a second of footage, which is a stronger form of justification than any vendor in the coding category offers. The unanswered question is WHO reviews. Clinician reviewed before every submission does not say whether the reviewer is the operating surgeon who performed the case or a reviewer employed by Uncovr, and those are entirely different oversight models with different accountability. Also missing: any published rate at which the reviewer disagrees with the draft, any confidence threshold, and any statement of behaviour when the video is obscured, which is routine in laparoscopy.

The product interface demonstrates what the system outputs, showing step segmentation with named instruments and procedural phases against a timeline, but the mechanism behind it is undescribed. No model is named, no architecture is given, there is no description of training data or how procedures were annotated, and no evaluation methodology or accuracy figure for the vision models is published. References to our models and our agents carry no further detail. The chief technology officer's background in autonomous tracking systems at the European Space Agency and ETH Zurich is credible provenance but it is not disclosure about this product.

Uncovr does something this index rewards, publishing denominators alongside its figures, and it still lands at C because of what the figures measure. Credit first: the company labels its foregut analysis with N equals 100 and cites an HCA Healthcare series at N equals 1,011, where most vendors publish percentages with no denominator at all. The problem is that the two numbers are of different kinds and appear under one heading reading real results. The foregut figure, 16 percent of revenue lost to poor documentation and undercoding, is Uncovr's own deployment finding with no stated methodology, cohort definition or comparison arm. The HCA figure, 70 percent of recommended detail missing correlating with reoperation, readmission and surgical site infection rates, measures how poor operative reports are in general. It characterises the PROBLEM Uncovr addresses, not Uncovr's PERFORMANCE against it, and presenting the two together invites a reader to attribute both to the product. Beyond that: no peer reviewed publication, no accuracy or completeness measurement of Uncovr's own output against a reference standard, and the Moon Surgical deployment reports 20 cases. The company was founded in 2025, so a thin evidence base is expected rather than damning, but it is thin.

The most specific architectural commitment located for any video based product in this index, and it is four distinct claims rather than one slogan: a zero PHI architecture, on device anonymisation performed BEFORE any processing, end to end encryption, and customer controlled retention. If accurate, identifiable data never leaves the operating room, which addresses the central exposure of surgical video head on. Held at B rather than A for two reasons. Nothing is independently verified and no attestation covers it. And the number that matters most is absent, exactly as this index records for C-SATS: there is no published de identification error rate, and a de identification failure on operating room video discloses PHI of an unusually intimate kind. Surgical video can carry faces, tattoos, distinguishing anatomy and the voices and images of theatre staff, and nothing published states what the anonymisation covers or how it was validated. Ask for the error rate and the scope before treating zero PHI as established.

No statement of HIPAA compliance, business associate agreement availability or terms was located, and no GDPR position is published either. That gap is notable rather than routine because the company operates on both sides of the Atlantic, with offices in Paris and New York, named United States surgeon advocates and a cited HCA Healthcare series, so both regimes plausibly apply and neither is addressed. A privacy policy and terms exist as separate pages but no compliance posture is asserted on the public site.

The security section is headed enterprise grade security and controls, and enterprise grade is a marketing adjective that this index tracks on a watchlist rather than treating as evidence. What sits under it is better than the heading: four specific technical commitments covering anonymisation, encryption and retention. What is entirely absent is any third party assurance. No SOC 2 of either type, no HITRUST, no ISO 27001, no penetration test summary, no trust centre and no report request path. Graded C rather than Not Rated because concrete controls are described, but a health system security review will ask for an attestation and there is none to point at.

No device authorisation and none apparently required, since generating documentation and proposing codes are not clinical determinations about a patient. The live regulatory surface is different and unaddressed. In the United States, procedural coding sits under False Claims Act exposure, and a product whose headline value is recovering revenue from previously unbilled steps places that exposure squarely on the customer. The video linked evidence is a genuinely strong answer to that risk, discussed on the governance axis, but no compliance position, coding audit methodology or documented regulatory analysis is published. For the French entity, any drift from documentation into clinical claims would raise EU medical device questions; nothing indicates such a claim is being made.

No fairness, subgroup or performance variation disclosure was located. The more consequential governance question is the revenue gradient, and Uncovr occupies a genuinely new position on it that deserves stating fairly in both directions. Every vendor this index tracks on coding intensity infers what was done from what was documented, which is why upcoding risk is intrinsic to the category. Uncovr inverts the evidence: it proposes a code and attaches the video timestamp where the act occurs. That is the first evidentially grounded justification for additional codes the index has assessed, and it is a real defence rather than a marketing line. Against it: the product is marketed heavily on recovery, with revenue lost framing, a revenue cycle audience and revenue recovery among its named uses, and a model optimised to surface billable steps carries an incentive gradient regardless of how good its evidence is. Video does not settle whether footage actually supports a given code, which remains a clinical and coding judgment. Separately, and applying this index's unadjusted benchmarking finding from Theator and Caresyntax: timestamped step level data on named surgeons is precisely the substrate for comparative performance analysis, and nothing published states whether it will be used that way or with what risk adjustment.

Strong on the side that captures data, undocumented on the side that has to receive it. Uncovr states it connects to any operating room video source across laparoscopic, robotic and any device, and it has a demonstrated platform integration: in June 2026 it became the first third party AI application running on Moon Surgical's Maestro platform. That is real device layer interoperability. But the output of this product is an operative report and a set of codes, and both must reach the electronic health record and the billing system to be useful. No EHR is named, no HL7 or FHIR write back path is described, and no reference integration is cited. The contrast inside this index is instructive: Theator, working with the same raw material, earned a top interoperability grade for native structured write back into Oracle Health. Until that path is documented, a buyer should assume the report needs to be moved manually.

Better described than most because the architecture forces a statement: anonymisation runs ON DEVICE before any processing, so the first stage of the pipeline is edge compute inside the operating room rather than a cloud upload of raw video. The company also states that customer data is retained on the customer's terms, which implies configurable retention rather than a fixed vendor policy. What is not published: where post anonymisation processing occurs, which cloud or region, tenancy model, and whether European and United States customers are served from separate infrastructure, which matters for a company operating from Paris and New York with customers in both markets.

No price, tier or pricing unit is published and every path routes through a booked demo. The unit question is unusually consequential here because the product's stated value is expressed in recovered revenue: pricing per operating room, per procedure, per surgeon or as a share of recovered reimbursement produce very different incentive structures, and the last of those would tie the vendor's compensation directly to coding intensity. Per this index's standing contingent pricing check, establish in writing whether any fee component varies with codes captured, claims value or revenue recovered.

Scoped to procedures that generate video, which is the natural boundary: laparoscopic, robotic and endoscopic surgery. Within that the reach is real, with a stated deployment pipeline above 400 operating rooms across the United States and Europe and thousands of hours of surgical video analysed. Breadth across every surgical specialty is claimed but the evidence concentrates in one area: the published study is foregut surgery, and the named surgeon advocates are foregut, hepatopancreatobiliary, minimally invasive and robotic specialists. That is a coherent beachhead rather than a weakness, but a buyer in orthopaedics, gynaecology or cardiothoracic surgery should ask what has actually been validated in their specialty. Open surgery, which generates no scope video, is outside the model entirely.